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period followed by a 10-week, randomized, double-blind,
placebo-controlled period. A total of 170 patients were random-
ized to receive a physician-determined dose of botulinium toxin
type A (BoNT-A) or placebo. Functional disability was measured
by patients and physicians using a scale from 0 (no functional
disability) to 4 (very severe disability). Functional disability was
measured at study visits at weeks 2, 4, 6, 8, and 10 of the
randomized, double-blind period of the study. RESULTS: The
baseline mean physician-assessed functional disability scores
were 1.87 for botulinium toxin and 1.88 for placebo. The mean
change in physician-assessed functional disability showed a
greater reduction in the BoNT-A group compared with the
placebo group at all timepoints, with the difference being signiﬁ-
cant at weeks 4, 6, and 8 (P  0.029). A higher proportion of
patients had a decrease of one grade or more in physician-
assessed functional disability in the BoNT-A group at all time
periods. The baseline mean patient-assessed functional disability
scores were 1.95 in the BoNT-A group and 1.78 in the placebo
group. A greater reduction in the mean change of patient-
assessed functional disability was seen with BoNT-A compared
with placebo at all timepoints. The patient-assessed functional
disability between the two groups was signiﬁcantly different at
weeks 2, 6, 8, and 10 (P  0.008). A one grade or greater
reduction in patient-assessed functional disability was experi-
enced by a higher proportion of botulinium toxin patients at all
timepoints compared with placebo. Rates of adverse events were
nearly equivalent between groups (59.1% BoNT-A vs. 58.5%
placebo group). CONCLUSION: Treatment with BoNT-A
showed signiﬁcant and sustained improvements in functional
disability when assessed by both the physician and the patient.
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OBJECTIVE: Most Multiple Sclerosis (MS) clinical trials focus
on relapses and MRI measures of disease activity. Disease
outcome measures in clinical trials and practice focus on physical
outcomes and, in particular, the ambulation oriented Expanded
Disability Severity Scale (EDSS). This study evaluated the rela-
tionships between various physical and patient reported out-
comes (PROs) in MS patients. METHODS: Charts were
abstracted for 98 MS patients in a single MS center that captured
both physician-evaluated outcomes and PROs. This study
reports the last available evaluation. Spearman rank correlations
and a recursive partitioning algorithm were used to evaluate
relationships between ﬁve physical (box/blocks, 9-hole peg,
timed walk, Tinetti balance, and EDSS) and 3 PRO (modiﬁed
fatigue impact scale, Beck depression inventory, and Espworth
sleepiness scale) measures in addition to standard demographic
and disease characterizing variables. RESULTS: The rank corre-
lation between the box/blocks and nine-hole peg tests (standard
tests for ﬁne motor control) was 0.9 (p < 0.001) while the rank
correlation between box/blocks and timed walk was 0.71
(p < 0.001). Moderate correlations were observed for the PROs:
fatigue and depression was 0.57 (p < 0.001); fatigue and sleepi-
ness was 0.52 (p < 0.001); and depression and sleepiness was
0.39 (p < 0.001). No signiﬁcant correlations were observed
between either depression or sleepiness and any physical
outcome measure. Fatigue was correlated with 9-hole peg (0.41,
p = 0.023), timed walk (0.44, p = 0.014), and EDSS (0.34,
p = 0.013). The recursive partitioning algorithm found the stron-
gest physical outcome associated with fatigue to be EDSS and the
best split was at EDSS <= (“minimal” versus “mild” disability).
CONCLUSION: Moderate correlations were found within the
physical outcome measures and within PROs; but the relation-
ship between physical outcomes and PROs was weak. Because
most clinical trials and evaluating neurologists focus on physical
measures in MS, it is likely that much of the disease impact is
being missed.
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OBJECTIVE: To evaluate investigator and patient-reported sat-
isfaction and ease-of-use of Azilect(r) (rasagiline tablets) in com-
munity neurological practices. Rasagiline is a potent, once daily,
novel, irreversible MAO-B inhibitor approved for PD as initial
monotherapy or adjunct therapy. Pivotal trials showed improve-
ment in the Uniﬁed Parkinson’s Disease Rating Scale for mono-
therapy and reduced OFF time for adjunct therapy. Other
measures of patient- and investigator-reported outcomes may
be important such as ease-of-use and patient satisfaction.
METHODS: LEGATO is an open-label study of once-daily rasa-
giline 0.5 mg and 1 mg in PD patients at 38 community-based
centers. Baseline treatment determined patients’ stratiﬁcation to
adjunct or monotherapy. Evaluations were at weeks 1, 2, 4, and
12. Endpoints included: patient and investigator reported Clini-
cal Global Improvement(CGI) score; investigator-and patient-
reported change from baseline in Schwab & England Activities
of Daily (ADL) score; and investigator-and patient-reported
satisfaction/ease-of-use ratings. RESULTS: A total of 272
patients were enrolled: 123 monotherapy patients and 149
adjunct patients with 245 completers. At all visits, investigator
reported CGI was signiﬁcantly improved for both mono and
adjunct therapy (p < 0.001). At all visits, patient reported CGI
was also signiﬁcantly improved for both mono and adjunct
therapy (p < 0.001). Patient-reported CGI was similar to Inves-
tigators’, although maximal improvement occurred later for
patients. Median satisfaction/ease-of-use scores were 9 for mono-
therapy (range 6 to 30 with 6 being best) and 10 for adjunct
therapy (range of 8 to 40 with 8 being best) for both patients
and investigators. Investigators noted statistically signiﬁcant
improvement in ADL of 3 points at the end of 12 weeks, whereas
patients did not note changes from baseline. CONCLUSION:
Both investigators and patients noted signiﬁcant effectiveness
beginning at week one as measured by CGI, found rasagiline
convenient and easy to use, and were satisﬁed with the dosing
frequency and tolerability of once-daily rasagiline.
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OBJECTIVE: The purpose of this study was to develop an instru-
ment to assess treatment satisfaction for patients with insomnia.
METHODS: Speciﬁc patient satisfaction items were identiﬁed
from the existing literature by an expert panel of physicians,
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